Boston (Mass.) Children’s Hospital has launched a neurologic drug research program through a new research agreement focused on developing therapies for patients with unmet medical needs.
The agreement builds on a strategic collaboration announced in July 2025 with NS Pharma, according to a June 23 news release. Boston Children’s Hospital proposed the research themes that were selected as joint research programs under the new arrangement.
The hospital will combine its research capabilities with industry drug discovery expertise to accelerate development of new neurologic therapies. Work under the agreement may range from early investigations into neurological disease mechanisms to identifying and validating potential therapeutic targets.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
